[1] Rockenstein E, Ubhi K, Doppler E, Novak P, Moessler H, et al. Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AβPP transgenic mice. J Alzheimers Dis. 2011;27(4):743-52.
[2] Dobrigna M, Poëa-Guyon S, Rousseau V, Vincent A, Toutain A, Barnier JV. The molecular basis of p21-activated kinase-associated neurodevelopmental disorders: From genotype to phenotype. Front Neurosci. 2023 Mar 2;17:1123784.
[3] Fuchsova B, Alvarez Juliá A, Rizavi HS, Frasch AC, Pandey GN. Expression of p21-activated kinases 1 and 3 is altered in the brain of subjects with depression. Neuroscience. 2016 Oct 1;333:331-44.
[4] Pütz SM, Kram J, Rauh E, Kaiser S, Toews R, Lueningschroer-Wang Y, Rieger D, Raabe T. Loss of p21-activated kinase Mbt/PAK4 causes Parkinson-like phenotypes in Drosophila. Dis Model Mech. 2021 Jun 1;14(6):dmm047811.
[5] Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015 Dec 10;11(6):1164-78.
[6] Bin Li, Lukas Wanka, Julie Blanchard, Fei Liu, Muhammad Omar Chohan, Khalid Iqbal, Inge Grundke-Iqbal, Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice, FEBS Letters, Volume 584, Issue 15, 2010, Pages 3359-3365.
[7] Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP, Morihara T, Ubeda OJ, Ambegaokar S, Hansen JE, Weisbart RH, Teter B, Frautschy SA, Cole GM. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci. 2006 Feb;9(2):234-42.
[8] Papismadov N, Gal H, Krizhanovsky V. The anti-aging promise of p21. Cell Cycle. 2017;16(21):1997-1998.
[9] Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009 Jun;9(6):400-14.